{"id":7100,"date":"2019-12-11T17:22:19","date_gmt":"2019-12-11T11:52:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7100"},"modified":"2025-05-08T12:51:59","modified_gmt":"2025-05-08T07:21:59","slug":"gaucher-disease-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market","title":{"rendered":"Gaucher disease Market Analysis: Rich Pipeline Drives the Market Ahead"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a13d84d5e0df\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a13d84d5e0df\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market\/#Why_the_variability\" >Why the variability?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market\/#Gaucher_Disease_Treatment_Market\" >Gaucher Disease Treatment Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market\/#Gaucher_Disease_Pipeline\" >Gaucher Disease Pipeline<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market\/#Gaucher_Disease_Market_Forecast\" >Gaucher Disease Market Forecast<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline.<\/strong><\/p><\/blockquote>\n\n\n\n<p>According to the National Organization of Rare Diseases, <em>Gaucher disease is a rare, inherited, metabolic disorder, which is characterized by an accumulation of harmful fats, chiefly the glycolipid glucocerebroside, in the whole body, more prominently in bone marrow, spleen, and liver.<\/em> <\/p>\n\n\n\n<p style=\"color:#9f0d0d\" class=\"has-text-color has-background has-very-light-gray-background-color\">Despite being the most common lysosomal inherited disorder, Gaucher disease is a rare condition. <\/p>\n\n\n\n<p>Deficiency of enzyme glucocerebrosidase (GCase) which has an important role in breaking down a fatty chemicals glucocerebrosidase, leads to the developing of Gaucher Disease. The accumulation of glucosylceramide (GC) and glucosyl sphingosine (GS) in lysosomes is considered one significant pathogenesis of the Gaucher disease. <\/p>\n\n\n\n<p>Gaucher Disease can be segmented into three divisions or types based on their characteristic features. <strong>Type 1 Gaucher Disease<\/strong>, the most common type of Gaucher disease, is a condition which does not affect the brain and spinal cord of the patient. Thus, it is a treatable form and is referred to as non-neuropathic Gaucher disease. Symptoms of Type 1 Gaucher disease include an increase in the size of the liver, and spleen, anaemia, decreased RBC count, decreased platelets, bone abnormalities and lung diseases. <\/p>\n\n\n\n<p><strong>Type 2 and 3 Gaucher disease <\/strong>are neuropathic Gaucher disease since they afflict the central nervous system of the patient. Type 2 and 3 Gaucher diseases are accompanied by neurological issues such as seizures, along with the symptoms of Type 1 Gaucher disease. However, the progression of Type 3 Gaucher disease is slower than the Type 2 Gaucher disease. The major reason <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_the_variability\"><\/span><strong>Why the variability? <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The associated mutations, which are the root cause of the Gaucher disease, are the main reason why the signs and symptoms differ with each type of Gaucher disease. As many as 300 types of mutations in the GBA gene are just associated with Type 1 Gaucher disease and over 50 mutations in the gene are behind the neuropathic forms of the Gaucher disease. Shockingly, the signs and symptoms of the disease vary with the disease. In a study, the symptoms of the Gaucher disease of one form failed to resemble the same form of the disease in different countries like China, Egypt and Sweden. This makes ethnical diversity another cause behind the varied symptoms and signs shown by the Gaucher disease patient pool. <\/p>\n\n\n\n<p>According to the National Gaucher Foundation, it can affect anyone, and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/gauchers-disease-market\">Gaucher disease prevalence<\/a><\/strong> is one in 40,000 live births. Gaucher disease is more common among Jews of Ashkenazi descent, and the figures in 2013 revealed that the Gaucher disease occurred in approximately 1 in 450, observed the NORD. Furthermore, 1 in 10 may also carry the mutated gene responsible for Gaucher disease.<\/p>\n\n\n\n<p>According to a study by Paul et al., Gaucher\ndisease prevalence was observed to be around 30 cases in one million of the\nGerman population. <\/p>\n\n\n\n<p>However, Type 1 or non-neuropathic Gaucher disease prevalence is observed to be around 90-95% of the total cases of the Gaucher disease in Europe and America, as presented by Stirnemann et al., in a review article. Moreover, the median age of the Gaucher disease diagnosis was observed to be from 10-20 years and the overall mean onset of patients is 20.4 years old, the majority of patients experienced onset before 20.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gaucher_Disease_Treatment_Market\"><\/span><strong>Gaucher Disease Treatment Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"has-background has-cyan-bluish-gray-background-color\"><strong>Gaucher disease has no cure. <\/strong><\/p>\n\n\n\n<p>However, in the past years, there has been an impressive scale of improvement in treating the symptoms of Gaucher disease Type 1. Significant cures to tackle bone abnormalities and organ enlargement are available in the Gaucher disease treatment market. <\/p>\n\n\n\n<p>Without a doubt, due to the diversity in the\nmutations and variability in the manifestations, severity, and progression, the\nGaucher disease treatment plan varies for the benefit of the patient. <\/p>\n\n\n\n<p>The major goals of the Gaucher Disease Type 1 treatment are to prevent any permanent harm to the body. <strong>Enzyme Replacement Therapy<\/strong> (ERT) and <strong>Substrate Reduction Therapy<\/strong> (SRT) are the mainstays Gaucher disease Type 1 therapies used for improving the symptoms, prevention of irreversible complications, such as massive fibrous splenomegaly secondary osteoarthritis, vertebral compression, and other fractures; hepatic fibrosis and lung fibrosis. Overall, these therapies help in improving health and quality of life Gaucher Disease patients. <\/p>\n\n\n\n<p>Moreover, several pain reregulating therapies, blood transfusions, and orthopaedic surgery are used for Gaucher disease management. ERT helps in compensating the low levels of enzyme GBA, by providing Glucocerebrosidase into the Gaucher cells. Enzyme Replacement Therapy helps in providing relief from the symptoms associated with hematologic, visceral, and bone in the Gaucher disease patients. <\/p>\n\n\n\n<p>Some of the approved Gaucher disease Enzyme\nReplacement therapies are <strong>Cerezyme<\/strong> (imiglucerase), <strong>Elelyso<\/strong> (taliglucerase\nalfa), and <strong>Vpriv<\/strong> (velaglucerase alfa). <\/p>\n\n\n\n<p>In the absence of ERT, <strong>Substrate Reduction\nTherapy<\/strong> (SRT) rescues the patients from the heavy accumulation of glucocerebroside\n(GlcCer). Approved Type 1 Gaucher Disease Substrate Reduction Therapy are <strong>Cerdelga<\/strong>\n(eliglustat), a therapy by <strong>Genzyme<\/strong>; and <strong>Zavesca<\/strong> (miglustat), a\nproduct of <strong>Actelion Pharmaceuticals<\/strong>.<\/p>\n\n\n\n<p>Another therapeutic approach for treating Gaucher disease is Bone Marrow Transplantation. The therapy helps in replenishing the monocytes and preventing the problem of excess-accumulation. <\/p>\n\n\n\n<p>Symptomatic treatment options for Gaucher disease include various pain reduction therapies, blood transfusions, orthopaedic surgery for bone and joints, and rare splenectomy. <\/p>\n\n\n\n<p>In case of failure of ERT, <strong>splenectomy<\/strong> is used for the Gaucher disease patients, since it also increases the risk of developing infection, thrombosis, or neoplasia. Moreover, to help patients with pathological fractures and bone complications, <strong>Orthopedic surgery<\/strong> is recommended.<\/p>\n\n\n\n<p> The growing demand for the standard and effective treatment option for Gaucher disease are driving the Gaucher disease treatment market forward. Looking at a number of unmet needs in Gaucher disease, there has been a large scale of Research being done to improve the Gaucher disease treatment landscape, yet there is a long way to go. <\/p>\n\n\n\n<p>Presence of substantial therapies are one thing, and their likeliness to be used by the patients is another. Researchers have long been focused on finding a permanent cure in the form of <strong>Gene therapy<\/strong> for genetic disorders like Gaucher disease. <\/p>\n\n\n\n<p>There remains a high unmet need for the development of improved treatments that combat neuronopathic complications at reduced costs and convenient administration schedule. Nevertheless, according to DelveInsight\u2019s analysts, a hike in funding in research and healthcare facilities to treat<strong> rare diseases<\/strong> patients are projected to shape the future of the Gaucher disease treatment market. Also, an upsurge in the Gaucher disease prevalence will drive the demands in Gaucher disease treatment market. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gaucher_Disease_Pipeline\"><\/span><strong>Gaucher Disease Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With a motive to treat a morbid and burdensome\nrare inherited autosomal recessive disease, many pharma companies and\nhealthcare institutions are investing to fuel the Gaucher disease market\nforward. In addition to these, some pharma companies have recently entered the\nGaucher disease market. <\/p>\n\n\n\n<p>Pharma companies like <strong>Sanofi-Genzyme<\/strong>, <strong>Orphazyme<\/strong>, <strong>AvroBio<\/strong>, <strong>Amicus therapeutics<\/strong>, <strong>Shire Plc<\/strong>, <strong>Cinven<\/strong> <strong>Ltd<\/strong>., <strong>Bluefish Pharmaceuticals<\/strong>, and many others are running clinical trials of their respective therapies to shape Gaucher disease market and help Gaucher disease patient pool to improve their quality of living. <\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"772\" height=\"482\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170737\/Gaucher-disease-key-company.jpg\" alt=\"Gaucher Disease Companies \" class=\"wp-image-7103\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170737\/Gaucher-disease-key-company.jpg 772w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170737\/Gaucher-disease-key-company-300x187.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170737\/Gaucher-disease-key-company-768x480.jpg 768w\" sizes=\"(max-width: 772px) 100vw, 772px\" \/><figcaption><strong>Gaucher Disease Companies <\/strong><\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gaucher_Disease_Market_Forecast\"><\/span><strong>Gaucher Disease Market Forecast<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Gaucher Disease type 1 market landscape is\nanticipated to change in the coming years, as per DelveInsight\u2019s market\nobservations, attributing to the improvement in the diagnosis methodologies, rising\nawareness of the diseases, incremental healthcare spending across the world, better\nhealthcare insurance. The launch of emerging Gaucher disease therapies during\nthe forecast period of 2019\u20132028 will further steer the Gaucher disease market\nin the right direction. <\/p>\n\n\n\n<p><strong>Venglustat<\/strong> (also known as GZ402671, Ibiglustat) is under\ndevelopment by <strong>Sanofi-Genzyme<\/strong>. The candidate is in Phase II stage\nof development of Gaucher Disease Type 1 and 3 treatment. Similarly, <strong>Arimoclomol<\/strong>\n(also known as BRX-345; OR-01) is under development by <strong>Orphazyme<\/strong>. The\ndrug candidate is in Phase II stage development for Gaucher Disease Type 1 and\n3 treatment.<\/p>\n\n\n\n<p>Another promising agent such as <strong>AvroBio\u2019s<\/strong> drug <strong>AVR-RD-02<\/strong>, is currently in phase I\/II of the clinical trials in the race of tackling Gaucher disease. It is an ex-vivo lentiviral-based investigational gene therapy which holds the promise to provide a life-long therapeutic benefit to Gaucher disease patient pool. <\/p>\n\n\n\n<p>Recently, in October 2019, the US Food and Drug\nAdministration (FDA) has also granted Orphan-Drug Designation to <strong>AVR-RD-02\nfor <\/strong>Gaucher disease. The recommendation came after the successful results\nof the therapy in terms of safety and efficacy to treat Gaucher disease Type 1.\n<\/p>\n\n\n\n<p>The Gaucher Disease type 1 pipeline boasts of a bright future for the Gaucher disease patients in the coming years.&nbsp; The current <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/gauchers-disease-market\">Gaucher disease market scenario<\/a><\/strong> also anticipates a positive shift in the market for a study period of 2017\u20132028.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline. According to the National Organization of Rare Diseases, Gaucher disease is a rare, inherited, metabolic disorder, which is characterized by an accumulation of harmful fats, chiefly the glycolipid glucocerebroside, in the whole body, more prominently in bone [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7102,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[17881,4296,17884,17886,17885,254,17879,1238,1233,1235,17608,17878,17882,17880,7281,17883,502,533,852],"industry":[17225],"therapeutic_areas":[17234],"class_list":["post-7100","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-actelion-pharmaceuticals","tag-amicus-therapeutics","tag-avrobio","tag-bluefish-pharmaceuticals","tag-cinven","tag-gaucher-disease","tag-gaucher-disease-enzyme-replacement-therapies","tag-gaucher-disease-market","tag-gaucher-disease-market-forecast","tag-gaucher-disease-market-size","tag-gaucher-disease-pipeline","tag-gaucher-disease-treatment-market","tag-gaucher-disease-type-1-pipeline","tag-genzyme","tag-orphan-condition","tag-orphazyme","tag-rare-disease","tag-sanofi","tag-shire","industry-pharmaceutical","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gaucher Disease Market Forecast | Gaucher Disease Emerging Therapies<\/title>\n<meta name=\"description\" content=\"Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline. Delveinsight..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gaucher Disease Market Forecast | Gaucher Disease Emerging Therapies\" \/>\n<meta property=\"og:description\" content=\"Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline. Delveinsight..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-11T11:52:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T07:21:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170354\/Gaucher-disease.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gaucher Disease Market Forecast | Gaucher Disease Emerging Therapies","description":"Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline. Delveinsight..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market","og_locale":"en_US","og_type":"article","og_title":"Gaucher Disease Market Forecast | Gaucher Disease Emerging Therapies","og_description":"Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline. Delveinsight..","og_url":"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-12-11T11:52:19+00:00","article_modified_time":"2025-05-08T07:21:59+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170354\/Gaucher-disease.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market","url":"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market","name":"Gaucher Disease Market Forecast | Gaucher Disease Emerging Therapies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170354\/Gaucher-disease.jpg","datePublished":"2019-12-11T11:52:19+00:00","dateModified":"2025-05-08T07:21:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline. Delveinsight..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/gaucher-disease-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170354\/Gaucher-disease.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170354\/Gaucher-disease.jpg","width":772,"height":482,"caption":"Gaucher disease Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/11170354\/Gaucher-disease-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Actelion Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Amicus therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">AvroBio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Bluefish Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Cinven<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gaucher disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gaucher Disease Enzyme Replacement Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gaucher Disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gaucher Disease market forecast<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gaucher Disease market size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gaucher Disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gaucher Disease Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gaucher Disease Type 1 Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Genzyme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">orphan condition<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Orphazyme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Rare Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Shire<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Actelion Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Amicus therapeutics<\/span>","<span class=\"advgb-post-tax-term\">AvroBio<\/span>","<span class=\"advgb-post-tax-term\">Bluefish Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Cinven<\/span>","<span class=\"advgb-post-tax-term\">Gaucher disease<\/span>","<span class=\"advgb-post-tax-term\">Gaucher Disease Enzyme Replacement Therapies<\/span>","<span class=\"advgb-post-tax-term\">Gaucher Disease market<\/span>","<span class=\"advgb-post-tax-term\">Gaucher Disease market forecast<\/span>","<span class=\"advgb-post-tax-term\">Gaucher Disease market size<\/span>","<span class=\"advgb-post-tax-term\">Gaucher Disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Gaucher Disease Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Gaucher Disease Type 1 Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Genzyme<\/span>","<span class=\"advgb-post-tax-term\">orphan condition<\/span>","<span class=\"advgb-post-tax-term\">Orphazyme<\/span>","<span class=\"advgb-post-tax-term\">Rare Disease<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Shire<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Dec 11, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Dec 11, 2019 5:22 pm","modified":"Updated on May 8, 2025 12:51 pm"},"featured_img_caption":"Gaucher disease Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7100"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7100\/revisions"}],"predecessor-version":[{"id":31943,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7100\/revisions\/31943"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7102"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7100"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7100"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}